Blood Test Predicts Response to Immunotherapy in Metastatic NSCLC
By LabMedica International staff writers Posted on 10 Mar 2020 |
![Image: Immunohistological micrograph showing a programmed death-ligand 1 (PD-L1) positive non-small cell lung carcinoma (Photo courtesy of Creative Commons BY-SA 4.0/Wikimedia). Image: Immunohistological micrograph showing a programmed death-ligand 1 (PD-L1) positive non-small cell lung carcinoma (Photo courtesy of Creative Commons BY-SA 4.0/Wikimedia).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2020-03-10/RLJ-098A.jpg)
Image: Immunohistological micrograph showing a programmed death-ligand 1 (PD-L1) positive non-small cell lung carcinoma (Photo courtesy of Creative Commons BY-SA 4.0/Wikimedia).
Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations.
NSCLC is the most common form of lung cancer, accounting for about 84% of all lung cancer cases. In patients with metastatic disease the five-year survival rate is just 6%. Immunotherapy with a PD-1 inhibitor, either alone or in combination with chemotherapy, is the standard first-line treatment in these cases when cancers do not have a targetable mutation.
Oncologists at the University of Pennsylvania (Philadelphia, PA, USA) and their colleagues enrolled 66 patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC) starting first-line pembrolizumab-based therapy, either alone or in combination with chemotherapy. Response was assessed using response evaluation criteria in solid tumors (RECIST 1.1.) rules. Associations were made for patient characteristics, 6-month durable clinical benefit (DCB), progression free survival (PFS), and overall survival (OS).
With a simple blood draw, the scientists can screen for mutations in 500 different genes. They used this liquid biopsy panel to measure the tumor mutational burden (TMB), essentially the number of mutations detectable in the blood of the enrolled patients, 52 of whom were evaluable for the trial. TMB is typically reported as mutations per megabase (Mb), which is the number non-synonymous, somatic mutations divided by the size of the genome coding area. The median TMB was 16.8 mutations per Mb and was significantly higher for patients who experienced a durable clinical benefit (DCB) compared to those who did not. A DCB means a patient experienced a complete response, a partial response, or stable disease for more than six months. Patients who achieved a DCB had a median of 21.3 mutations per Mb, compared to 12.4 in patients who did not achieve a DCB.
The team then examined the progression-free survival (PFS) and overall survival (OS) of both groups. The 28 patients with more than 16 detectable mutations per Mb had a median PFS of 14.1 months compared to 4.7 months for the 24 patients in the lower TMB group. Median OS was not reached for the high TMB group. The low TMB group had a median OS of 8.8 months.
Erica L. Carpenter, MBA, PhD, an assistant professor and senior author of the study, said, “We believe this is the largest study to show correlation between blood-based tumor mutational burden and clinical outcomes after first-line PD-1-based treatment, including combination chemo-immunotherapy, for NSCLC.”
The authors concluded that pTMB greater than or equal to 16 mutations/Mb is associated with improved PFS after first-line standard of care pembrolizumab-based therapy in mNSCLC. STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond. The study was published on February 26, 2020 in the journal Clinical Cancer Research.
Related Links:
University of Pennsylvania
NSCLC is the most common form of lung cancer, accounting for about 84% of all lung cancer cases. In patients with metastatic disease the five-year survival rate is just 6%. Immunotherapy with a PD-1 inhibitor, either alone or in combination with chemotherapy, is the standard first-line treatment in these cases when cancers do not have a targetable mutation.
Oncologists at the University of Pennsylvania (Philadelphia, PA, USA) and their colleagues enrolled 66 patients with newly diagnosed metastatic non-small cell lung cancer (mNSCLC) starting first-line pembrolizumab-based therapy, either alone or in combination with chemotherapy. Response was assessed using response evaluation criteria in solid tumors (RECIST 1.1.) rules. Associations were made for patient characteristics, 6-month durable clinical benefit (DCB), progression free survival (PFS), and overall survival (OS).
With a simple blood draw, the scientists can screen for mutations in 500 different genes. They used this liquid biopsy panel to measure the tumor mutational burden (TMB), essentially the number of mutations detectable in the blood of the enrolled patients, 52 of whom were evaluable for the trial. TMB is typically reported as mutations per megabase (Mb), which is the number non-synonymous, somatic mutations divided by the size of the genome coding area. The median TMB was 16.8 mutations per Mb and was significantly higher for patients who experienced a durable clinical benefit (DCB) compared to those who did not. A DCB means a patient experienced a complete response, a partial response, or stable disease for more than six months. Patients who achieved a DCB had a median of 21.3 mutations per Mb, compared to 12.4 in patients who did not achieve a DCB.
The team then examined the progression-free survival (PFS) and overall survival (OS) of both groups. The 28 patients with more than 16 detectable mutations per Mb had a median PFS of 14.1 months compared to 4.7 months for the 24 patients in the lower TMB group. Median OS was not reached for the high TMB group. The low TMB group had a median OS of 8.8 months.
Erica L. Carpenter, MBA, PhD, an assistant professor and senior author of the study, said, “We believe this is the largest study to show correlation between blood-based tumor mutational burden and clinical outcomes after first-line PD-1-based treatment, including combination chemo-immunotherapy, for NSCLC.”
The authors concluded that pTMB greater than or equal to 16 mutations/Mb is associated with improved PFS after first-line standard of care pembrolizumab-based therapy in mNSCLC. STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond. The study was published on February 26, 2020 in the journal Clinical Cancer Research.
Related Links:
University of Pennsylvania
Latest Molecular Diagnostics News
- Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
Channels
Clinical Chemistry
view channel![Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF) Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-27/98234491_m_normal_none.jpg)
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more![Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT) Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-10/MIT-Printed-Ion-01-press_0.jpg)
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more![Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University) Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-14/Spinning-Glowing (1).jpg)
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more![Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University) Image: The new versatile assay has the ability to measure both total and bioavailable cortisol from serum (Photo courtesy of Aarhus University)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-04/ac3c04435_0004.jpg)
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read moreMolecular Diagnostics
view channel![Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics) Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-14/2024_Doctor-Holding-Kit.jpg)
Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more![Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche) Image: The cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test runs on the cobas liat system (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-13/image-media-info-cobas-liat-system-tube.jpg)
Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
The U.S. Centers for Disease Control and Prevention (CDC) has reported that respiratory diseases in the United States reached high levels during the recent autumn and winter seasons, with SARS-CoV-2 leading... Read more![Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock) Image: Screening for prostate cancer with first-line MRI is less cost-effective than first-line PSA testing (Photo courtesy of Adobe Stock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-12/AdobeStock_480745598 (1).jpeg)
First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
Current prostate cancer (PCa) screening protocols typically begin with prostate-specific antigen (PSA) testing, which, if elevated, may lead to further assessment using multiparametric magnetic resonance... Read more![Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding) Image: The Olink Explore platform can identify proteins in blood that may provide a 7-year warning for various cancers (Photo courtesy of Olink Holding)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-11/proteomics-and-transcriptomics-1000x563.jpg)
Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
To improve cancer survival rates, it's crucial to understand the disease during its initial stages. Research involving data from thousands of cancer patients has uncovered exciting findings about how blood... Read moreHematology
view channel![Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia) Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/C3_DBS_Website.2.jpg)
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more![Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols) Image: The Procleix ArboPlex Assay has received the CE mark (Photo courtesy of Grifols)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-08/donor-testing-1.jpg)
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more![Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health) Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-03-20/news-7.jpg)
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more![Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health) Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-02-08/inserting-hb-variant-cartridge.jpg)
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel![Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute) Image: The AI tool predicts whether someone’s cancer will respond to immune checkpoint inhibitors (Photo courtesy of National Cancer Institute)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/Surgical oncology 43 (1).jpg)
AI Tool Predicts Cancer Patients’ Response to Immunotherapy
Immune checkpoint inhibitors are a form of immunotherapy drug that enables immune cells to target and destroy cancer cells. At present, the Food and Drug Administration has approved two predictive biomarkers... Read more![Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer) Image: Initially aimed at children with high-risk cancers, ZERO now includes all young cancer patients in Australia (Photo courtesy of Zero Childhood Cancer)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-03/906uv0fs34hr.jpg)
Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
Cancer remains the leading cause of disease-related death among children in most developed nations, and approximately one-fourth of these patients are diagnosed with aggressive, high-risk, or relapsed... Read moreMicrobiology
view channel![Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical) Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/device-front.jpg)
POC STI Test Shortens Time from ED Arrival to Test Results
In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more![Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock) Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-08/shutterstock_1065839396.jpg)
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more![Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB) Image: The ASTar System has received US FDA 510(k) clearance (Photo courtesy of Q-linea AB)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-07/ASTar_ft-1-700x494.jpg)
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more![Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche) Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-02/cobas-eplex-in-copy-image_2.jpg)
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read moreTechnology
view channel![Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet) Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-06-05/plaster_custom20240529112158.jpg)
Microneedle Patch Detects Skin Cancer Early
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes.... Read more![Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz) Image: The nanopore optofluidic chip used in the new diagnostic system (Photo courtesy of UC Santa Cruz)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-04-09/new-diagnostic-tool-ac.jpg)
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read moreIndustry
view channel![Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche) Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-28/download.jpg)
Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing
Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more![Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF) Image: Scientists will evaluate new blood-based biomarkers using highly sensitive technology (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-13/103048801_m_normal_none.jpg)
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more![Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter) Image: Beckman Coulter is now an authorized distributor of the MeMed Key immunoassay system and MeMed BV assay (Photo courtesy of Beckman Coulter)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-09/PR_partnership_with_Beckman_Coulter_v1_2.jpg)
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more![Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF) Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2024-05-01/130140677_m_normal_none (1)_1.jpg)